慢性粒细胞白血病异基因骨髓移植后残留白血病观察  

Detection of minimal residual disease after allogeneic bone marrow transplantation in chronic myeloid leukemia

作　　者：刘艳荣[1] 傅家瑜[1] 喻新建[1] 常艳 薛文韬[1] 陈珊珊[1] 陆道培[1] 

机构地区：[1]北京医科大学人民医院血液病研究所

出　　处：《中华血液学杂志》1997年第3期140-142,共3页Chinese Journal of Hematology

摘　　要：目的：观察慢性粒细胞白血病（ＣＭＬ）异基因骨髓移植（ａｌｏ－ＢＭＴ）后残留白血病情况。方法：用逆转录－多聚酶链反应（ＲＴ－ＰＣＲ）技术测定４６例经ａｌｏ－ＢＭＴ植活的ＣＭＬ患者骨髓细胞Ｍ－ｂｃｒ／ａｂｌｍＲＮＡ表达。结果：ａｌｏ－ＢＭＴ能使约７０％ＣＭＬ患者在移植后３个月ｂｃｒ／ａｂｌｍＲＮＡ转阴。其中４例患者在移植后＋１．５～２．０个月时为ｂｃｒ／ａｂｌｍＲＮＡ（＋），于＋３个月转为阴性；１例于＋９个月转阴。１例无病存活６年以上患者，其ｂｃｒ／ａｂｌｍＲＮＡ为阳性；另１例无病存活４年以上患者ｂｃｒ／ａｂｌｍＲＮＡ为阴性。结论：ＲＴ－ＰＣＲ是当前检测残留白血病最灵敏的方法，但不能忽视其局限性。Objective: To detect minimal residual disease (MRD) after allogeneic bone marrow transplantation (allo BMT) in chronic myeloid leukemia(CML). Methods:M bcr/abl mRNA was assayed by reverse transcriptase polymerase chain reaction (RT PCR) in bone marrow cells from 46 successfully sibling marrow engrafted CML patients.Results:About 70% of the patients achieved genetic complete remission in 3 months post allo BMT.Four patients were M bcr/abc mRNA positive at 1.5 to 2 months post allo BMT and turned to be negative at 3 to 9 months post allo BMT.One patient was still M bcr/abl(+)after disease free survival(DFS) for more than 6 years,while another one was M bcr/abl(-) after DFS for more than 4 years.Conclusion:RT PCR is so far the most sensitive method for MRD detection in CML ,but its limitation should not be ignored.

关 键 词：慢性 白血病 髓细胞性 骨髓移植 异基因 

分 类 号：R733.720.5[医药卫生—肿瘤]